Table 1 Baseline characteristics of randomized controlled trials included in the systematic review
Study | Country | Interventions (Number of Subjects; Mean Age [y]) | Grade of Osteoarthritis | Injection Interval | Outcome Reported (Follow-up) |
|---|---|---|---|---|---|
Görmeli, 2017 | Turkey | PRP1 (n = 44; 53.8) PRP3 (n = 39; 53.7) | Kellgren–Lawrence grades 0 to IV | 1 week | VAS (6 months) |
Kavadar, 2015 | Turkey | PRP1 (n = 34; 53.6) PRP2 (n = 34; 54.9) PRP3 (n = 34; 55.2) | Kellgren–Lawrence grade III | 2 weeks | VAS and WOMAC (1, 3, and 6 months) |
Lewis, 2022 | Australia | PRP1 (n = 47; 55.1) PRP3 (n = 27; 59.4) | Kellgren–Lawrence grades 0 to II | 1 week | VAS (1, 3, and 6 months) |
Patel, 2013 | India | PRP1 (n = 27; 53.1) PRP2 (n = 25; 51.6) | Ahlback grades I to III | 3 weeks | VAS (6 months) and WOMAC (1, 3, and 6 months) |
Simental-MendÃa, 2019 | Mexico | PRP1 (n = 18; 54.6) PRP3 (n = 17; 60.1) | Kellgren–Lawrence grades I and II | 2 weeks | VAS and WOMAC (1, 3, and 6 months) |
Subramanyam, 2021 | India | PRP1 (n = 30; 48.4) PRP2 (n = 30; 46.7) PRP3 (n = 30; 47.6) | Kellgren–Lawrence grades I and II | 2 weeks | VAS (1, 3, and 6 months) |
Tavassoli, 2019 | Iran | PRP1 (n = 27; 63.2) PRP2 (n = 27; 66.0) | Ahlback grades I and II | 3 weeks | VAS and WOMAC (3 and 6 months) |
Uslu Güvendi, 2018 | Turkey | PRP1 (n = 19; 62.3) PRP3 (n = 14; 60.4) | Kellgren–Lawrence grade III | 1 week | VAS and WOMAC (3 and 6 months) |
Yurtbay, 2022 | Turkey | PRP1 (n = 62; 53.3) PRP3 (n = 63; 57.4) | Kellgren–Lawrence grades I to III | 4 weeks | VAS (1, 3, and 6 months) |
Zhuang, 2024 | China | PRP1 (n = 36; 58.8) PRP3 (n = 35; 59.9) | Kellgren–Lawrence grades I to III | 1 week | VAS and WOMAC (1, 3, and 6 months) |